Sialic Acid-binding Ig-like Lectin 10: Potential Drug Target (G89790)

Target Name: SIGLEC10

NCBI ID: G89790

SIGLEC10

Sialic Acid-binding Ig-like Lectin 10: Potential Drug Target

Sialic acid-binding Ig-like lectin 10 (ISOFORM 1) is a protein that is expressed in many different tissues throughout the body, including the epithelial and nervous systems. It is characterized by its ability to bind to and interact with sialic acid, which is a carbohydrate found on the surface of many different cell types. This interaction between SIGLEC10 and sialic acid has important implications for the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SIGLEC10 is a member of the Ig-like lectin family, which includes a variety of proteins that are involved in the immune system. These proteins are characterized by their ability to recognize and bind to specific antigens, such as bacteria, viruses, and cancer cells. SIGLEC10 is unique, however, in its ability to interact with sialic acid, which is found on the surface of many different cell types.

Sialic acid is a carbohydrate that is found on the surface of many different cell types, including bacteria, viruses, and cells of the nervous system. It is made up of a sugar molecule and a protein that is responsible for its structure and function. Sialic acid is able to interact with many different proteins, including those that are involved in the immune system. This interaction between sialic acid and these proteins is important for the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of SIGLEC10 is its ability to recognize and bind to specific antigens. This is accomplished through the use of its extracellular domain, which is responsible for the formation of the protein's linear shape and its ability to interact with sialic acid. SIGLEC10's extracellular domain is composed of a single passband that is responsible for the formation of a unique structure that is able to interact with sialic acid.

SIGLEC10's ability to interact with sialic acid has important implications for the development and progression of many different diseases. For example, it has been shown to be involved in the development and progression of cancer, both in humans and in animal models. SIGLEC10 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, SIGLEC10 has been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

SIGLEC10 is also of interest as a potential drug target. Its ability to interact with sialic acid and its involvement in the immune system make it a potential target for small molecules that can be used to treat a variety of different diseases. For example, SIGLEC10 has been shown to be involved in the development and progression of cancer, both in humans and in animal models. Therefore, it is possible that small molecules that can inhibit its activity or its ability to interact with sialic acid could be used to treat cancer. Additionally, SIGLEC10's involvement in the immune system makes it a potential target for drugs that can be used to treat autoimmune disorders.

In conclusion, Sialic acid-binding Ig-like lectin 10 (ISOFORM 1) is a protein that is characterized by its ability to interact with sialic acid. This interaction has important implications for the development and progression of many different diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SIGLEC10 is a potential drug target that could be used to treat a variety of different diseases.

Protein Name: Sialic Acid Binding Ig Like Lectin 10

Functions: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- or alpha-2,6-linked sialic acid (By similarity). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, seems to act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules (PubMed:11284738, PubMed:12163025). Involved in negative regulation of B-cell antigen receptor signaling. The inhibition of B cell activation is dependent on PTPN6/SHP-1 (By similarity). In association with CD24 may be involved in the selective suppression of the immune response to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70 and HSP90 (By similarity). In association with CD24 may regulate the immune repsonse of natural killer (NK) cells (PubMed:25450598). Plays a role in the control of autoimmunity (By similarity). During initiation of adaptive immune responses by CD8-alpha(+) dendritic cells inhibits cross-presentation by impairing the formation of MHC class I-peptide complexes. The function seems to implicate recruitment of PTPN6/SHP-1, which dephosphorylates NCF1 of the NADPH oxidase complex consequently promoting phagosomal acidification (By similarity)

The "SIGLEC10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets